Patent FR964745A successfully refreshed from Google Patents.
Patent US5091391A successfully refreshed from Google Patents.
US5091391A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of resisting neurodegenerative disorders
Assignee: University of Pittsburgh
•
Filing: 1990-08-16
•
Granted: 1992-02-25
•
Expires: 2010-08-16
Abstract
Abstract A method for resisting neurological damage caused by overstimulation of theMDA receptor of nerve cells by glutamate includes exposing the NMDA receptors to an oxidizing agent to thereby diminish overall activity of the receptors following activation by glutamate. The oxidizing agent preferably is a material selected from the group consisting of pyrroloquinoline quinone and topa hydantoin.
Inventors
- 👤 Elias Aizenman
- 👤 Paul A. Rosenberg
- 👤 Paul M. Gallop
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 12:31
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
47 words
A method of resisting neurological damage in a subject caused by overstimulation of the NMDA receptors of nerve cells by glutamate comprising, administering to said subject an effective does of the oxidizing agent pyrroloquinoline quinone to thereby diminish the activity of NMDA receptors after activation by glutamate.
Claim 2
Independent Claim
47 words
A method of resisting neurological damage in a subject caused by overstimulation of the NMDA receptors of nerve cells by glutamate comprising, administering to said subject an effective does of the oxidizing agent pyrroloquinoline quinone to thereby diminish the activity of NMDA receptors after activation by glutamate.
Claim 3
Dependent Claim
13 words
The method of claim 1 including, employing said method on a human being.
Claim 4
Dependent Claim
13 words
The method of claim 1 including, employing said method to treat a patient.
Claim 5
Dependent Claim
11 words
The method of claim 3 including, administering said oxidizing agent orally.
Claim 6
Dependent Claim
14 words
The method of claim 4 including, employing said method to treat a stroke victim.
Claim 7
Dependent Claim
27 words
The method of claim 1 including, employing said method on a subject who is at risk or neurological damage from ischemia or anoxia as a prophylactic measure.
Claim 8
Dependent Claim
17 words
The method of claim 1 including employing said method on a patient suffering from a neurodegenerative disorder.
Claim 9
Dependent Claim
21 words
The method of claim 7 including, administering said oxidizing agent to said patient after an ischemic attack to limit infarct size.
Claim 10
Dependent Claim
18 words
The method of claim 1 including, effecting said oxidation at a redox modulatory site of said NMDA receptor.
Claim 11
Dependent Claim
21 words
The method of claim 1 including, employing said oxidation to convert sulfhydryl residue on the NMDA extracellular surface to disulfide bonds.
Claim 12
Independent Claim
36 words
A method of resisting neurological damage to neurons by overstimulation on the NMDA receptors of a patient comprising, administering to said patient an effective dosage of the oxidizing agent pyrroloquinoline quinone to diminish NMDA receptor activation.
Claim 13
Independent Claim
36 words
A method of resisting neurological damage to neurons by overstimulation on the NMDA receptors of a patient comprising, administering to said patient an effective dosage of the oxidizing agent pyrroloquinoline quinone to diminish NMDA receptor activation.
Claim 14
Dependent Claim
16 words
The method of claim 11, employing said method to resist glutamate damage via said NMDA receptors.
Claim 15
Dependent Claim
16 words
The method of claim 11, employing said method on a patient who has had a stroke.
Claim 16
Dependent Claim
20 words
The method of claim 11, effecting said diminishing of NMDA receptor activation at a redox modulator site of said receptor.
Claim 17
Dependent Claim
22 words
The method of claim 11, employing said oxidizing agent to convert vicinal sulfhydryl residue on said NMDA extracellular surface to disulfide bonds.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-24 | 1995-08-26 | 1996-02-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-24 | 1999-08-26 | 2000-02-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-24 | 2003-08-26 | 2004-02-25 | $7700.00 | Window Closed / Lapsed |